Electronic Publication of Patents Journal under The Patents (Amendments) Act, 2016

Weekending:- 19-06-2020

Legal Publication Date:- 10-08-2020

Journal Code (20810)

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

15/06/2020		
379/2020	LAKSHMI MACHINE WORKS LTD., India. (Priority 01/07/2019 IN)	''CAN EXCHANGING APPARATUS AND A METHOD THEREOF FOR A TEXTILE SPINNING PREPARATORY MACHINE''
380/2020	PFIZER INC., and CTXT PTY LTD. Australia. (Priority 18/06/2019 US)	"Benzisoxazole Sulfonamide Derivatives"
381/2020	Merck & Co.,Inc. U.S.A. (Priority 12/08/2008 US)	"SUBSTITUTED 1,2,4-TRIAZOLYL-DODECAHYDRO-TETRAMETHYL-4H-1,4a-PROPANO-2H-PHENANTHRO[1,2-c]PYRAN-7-CARBOXYLIC ACID"
382/2020	MUHAMMAD BILAL KHAN and MUHAMMAD USMA QURESHI. Pakistan.	"A NOVEL MACHINE FOR MARKETING PRODUCT ON SHELF"
383/2020	Zeeshan Khatri and Farooq Ahmed. Pakistan.	"Water repellent and washable Nanofiber Hybrid Face Mask for filtering Covid-19-Method of making and use thereof"
384/2020	Engr. Ali Imran, Engr. Abdullah Saqib, Mr. Imran Qureshi & Dr. Quratulain Syed. Pakistan.	"Development of Disinfection Corridor utilizing Mist Fan Technology"
385/2020	Habib Nasir and Anum Zahir Pakistan.	"Tetraphenylporphyrin Functionalized Pristine Graphene Based Nanosensors for Electrochemical Detection of Trace Nitrobenzene"
386/2020	Habib Nasir, Syeda Aqsa Batool Bukhari and Lujun Pan Chinese. Pakistan.	"Electrochemical Sensing of Catechol Based on Carbon Nanocoils/Zinc-Tetraphenyl"

387/2020	AKMAL JAVED (Retd) and PERVAIZ IQBAL. Pakistan.	"Preparation of Synthetic Pulp for edible juices and Making of Synthetic Pulp"
16/06/2020		
388/2020	Deciphera Pharmaceuticals, LLC., U.S.A. (Priority 17/06/2019 US & 17/06/2019 US)	"AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF"
389/2020	VIIV HEALTHCARE UK (No.5) LIMITED, United Kingdom. (Priority 19/06/2019 US)	"INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION"
390/2020	National University of Sciences & Technology (NUST), Pakistan.	"Liquid hand sanitizer for General Public"
391/2020	National University of Sciences & Technology (NUST), Pakistan.	"Gel-based Hand sanitizer"
17/06/2020		
392/2020	Saurer Spinning Solutions GmBH & Co. KG. Germany. (Priority 19/06/2019 DE)	"A TEXTILE MACHINE HAVING A PLURALITY OF WORKSTATIONS AND A METHOD FOR MONITORING A TEXTILE MACHINE A PLURALITY OF WORKSTATIONS"
393/2020	Saurer Spinning Solutions GmBH & Co. KG. Germany. (Priority 19/06/2019 DE)	"FIBRE BAND OPENING DEVICE FOR AN OPEN-END SPINNING DEVICE AND FEED TRAY FOR THE FIBRE BAND OPENING DEVICE"
394/2020	ELI LILLY AND COMPANY U.S.A. (Priority 28/06/2019 US)	"GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS"
395/2020	Visterra, Inc.	"Humanized antibody molecules to CD138 and

	U.S.A. (Priority 17/06/2019 US)	uses thereof"
396/2020	Khawar Nehal. Pakistan.	"Corner sensor and alert system for transport vehicles"
18/06/2020		
397/2020	Ch. Shahid Rahim, CEO, Agritec Industries Pvt Ltd, Pakistan.	"AGRITEC ULV SPRAYER"
398/2020	SHENZHEN STOCK EXCHANGE; China. (Priority 24/09/2019 CN)	"PROCESSING METHOD AND PROCESSING DEVICE FOR SENDING MESSAGES, AND COMPUTER READABLE STORAGE MEDIUM"
399/2020	G1 Therapeutics, Inc., Pakistan. (Priority 18/06/2019 US)	"MEANS FOR ENHANCEMENT OF ANTI-TUMOR IMMUNITY IN CANCER PATIENTS"
400/2020	SHENZHEN TRANSSION HOLDINGS CO., LTD.; China. (Priority 29/09/2019 CN)	"METHOD FOR IMPLEMENTING AUGMENTED REALITY, MOBILE TERMINAL, AND STORAGE MEDIUM"
401/2020	Hisham Saeed Aldajani son of Hisham Saeed Abdullah Abdulrahman Aldajani, Saudi Arabia.	"Device"
402/2020	Dr. Abdul Rehman. (Assistant Professor) Pakistan.	"MULTIFUNCTION SUGARCANE HARVESTING MACHINE"
403/2020	SANTONI S.P.A. Italy. (Priority 19/06/2019 IT)	"Circular knitting machine with system for offsetting the plate of the needles with respect to the cylinder of the needles"
404/2020	SANTONI S.P.A. Italy. (Priority 20/06/2019 IT)	"Turning device for tubular knitted items and method for turning tubular knitted items"
405/2020	Engr. Ali Imran,	"Paddle Based Mechanical Sanitizer Dispenser"

	Engr. Abdullah Saqib, Mr. Imran Qureshi & Mr. Muhammad Azhar, Pakistan.	
19/06/2020		
406/2020	JVCKENWOOD Corporation. Japan (Priority 25/06/2019 JP)	"MOVING PICTURE CODING DEVICE, MOVING PICTURE CODING METHOD, MOVING PICTURE CODING PROGRAM, MOVING PICTURE DECODING DEVICE, MOVING PICTURE DECODING METHOD, AND MOVING PICTURE DECODING PROGRAM"
407/2020	THE POPULATION COUNCIL INC. U.S.A. (Priority 21/06/2019 US)	"SYSTEM FOR PROVIDING BIRTH CONTROL"

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Patents' journal may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules **18(1) of 2003.**

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be as certained on application to the office.

282/2009	DUKE UNIVERSITY and IMMUNOLIGHT LLC, U.S.A.	''A pharmaceutical composition for producing a desired change in a target structure" A61K41/00, A61N5/10 & A61N5/06. **143510** The present invention relates to a pharmaceutical composition for producing a desired change in a target structure, comprising: an energy modulation agent, a pharmaceutically acceptable carrier and optionally a plasmonics-active agent, wherein the energy modulation agent and pharmaceutically acceptable carrier are present in a ratio sufficient for administration of the composition by a desired administration route; wherein the energy modulation agent receives higher energy X-rays and emits electromagnetic in lower energy UV and is selected from fluorescent molecules or luminescent molecules or phosphorescent molecules, and wherein the composition does not comprise an activatable pharmaceutical agent.

405/2010	BAYER CROPSCIENCE AG. Germany.	"N-BENZYL-N-CYCLOPROPYL-3-(DIHALOMETHYL)-5-HALO-1 -METHYL-PYRAZOLE-4-CARBOXAMIDE COMPOUND" A01N43/56, C07D401/12 & C07D231/16. **143511** The present invention relates to pyrazole carboxamide compound of formula (I)  (I) wherein Y represents CR^5 or N, T represents S or O, X1 and X2 represent a chlorine or a fluorine atom, and Z1 represents a substituted or non-substituted cyclopropyl.
592/2014	Ishihara Sangyo Kaisha, Ltd. and NIHON NOHYAKU CO., LTD. Japan.	"Water-Based Pesticidal Suspension Comprising (a) Flonicamid, (b) Buprofezin, (c) Polycarboxylate, (d) Surfactant (e) Sodium Alkylnaphthalenesulfonate condensed with formaldehyde and water" A01N43/40 , A01N25/30 & A01P7/04. **143512** The present invention provides a water-based pesticidal suspension comprising (a) flonicamid, (b) buprofezin, (c) a polycarboxylate, (d) at least one sulfonate type surfactant selected from the group consisting of an alkyl sulfosuccinate, a lignosulfonate, a C_{8-18} alkylbenzene sulfonate and a C_{8-18} alkyl diphenyl ether disulfonate, (e) a sodium alkylnaphthalenesulfonate condensed with formaldehyde, and water. The mean volume diameter of particles of active ingredients (a)

		flonicamid and (b) buprofezin, is from 0.1 µm to 20 µm. The present invention solves the problem of the prior art such that if a water-based pesticidal suspension containing (a) flonicamid and (b) buprofezin as active ingredients is stored for a long period of time, the active ingredient particles will grow and become coarse during storage, and a stable suspension is hardly obtained.
150/2015	Merck Sharp & Dohme Corp., U.S.A.	"4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR COMPOUND" C07D487/04, A61K31/7064 , A61P11/16 & C07D487/04. **143513** The invention relates to a compound of structural Formula I  I wherein: R is  X is O; Y is -C≡C-R^8 or -C≡N; Whereas the substituents including R^1 to R^9, R^x and R^Y are described in description and claims. The present invention also provides a pharmaceutical composition comprising a 4'-substituted nucleoside compound for inhibition of HIV reverse transcriptase, for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset of AIDS.

357/2015	CHIESI FARMACEUTICI S.p.A., Italy.	"INDOLIZINE AS PHOSHOINOSITIDE 3-KINASE INHIBITOR" C07D473/02,C07D471/04, C07D487/04,A61K31/519, A61K31/52,A61P37/00, A61P11/00 & A61P29/00. **143514** The invention relates to novel a compound of general formula (I)  (I) wherein X_1, X_2, X_3 and X_4, are all CH groups R, R_1, R_2, R_3, R_4, Cy, Z, m, n and p are as defined in therein, which are inhibitor of phosphoinositide 3-kinase, and composition containing them.
668/2015	ENI S.p.A., Italy.	"SAFETY VALVE FOR EXTRACTION WELLS OF HYDROCARBONS" E21B29/08 & E21B29/00. **143515** A safety valve (10) for extraction wells is described, configured for being installed on the head (11) of a well and for enclosing a portion of a tubular material (12) inserted inside the well. The tubular material (12) is internally hollow and designed for containing and transporting fluids and other substances extracted from the well. The safety valve (10) is provided with a central hole through which the tubular material (12) passes and comprises a blocking system (14, 16), configured for firmly keeping the tubular material

		(12) to be cut fixed with respect to the safety valve (10), a cutting and closing group (18) configured for cutting and closing the well under certain operative conditions, and a sealing mechanism (20), designed for effecting a watertight closing of the well, after the cutting. The cutting and closing group (18) consists of a hole saw (26) housed in a respective chamber of said cutting and closing group (18). The hole saw (26) is rotated by a motorized actuation means (28) and is configured for moving in a controlled mode along a substantially orthogonal direction with respect to the development direction of the well.
548/2016	Janssen Pharmaceuticals, Inc., and Katholieke Universiteit Leuven. U.S.A.	"1- (substituted- 1H-indol-3-yl)-2-(4-fluoro-2-(2-hydroxyethoxy)-phenyl)-2-((3-methoxy-5-(methylsulfonyl) phenyl)amino)ethanones with anti-dengue activity" C07D209/12, A61K31/454 & A61P31/14. **143516** The present invention relates to a compound of formula (I)  a stereo-isomeric form, solvate or polymorph thereof; said compound is selected from the group wherein: R_1 is H, R_2 is F or Cl and R_3 is H or CH_3; R_1 is F, R_2 is F and R_3 is H; R_1 is CH_3, R_2 is OCH_3 and R_3 is H; R_1 is CH_3, R_2 is F and R_3 is H; R_1 is CH_3, R_2 is H and R_3 is F; R_1 is Cl, R_2 is H and R_3 is CH_3; R_1 is OCF_3, R_2 is H or OCH_3 and R_3 is H and

		R_1 is OCF_3, R_2 is H and R_3 is CH_3 for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical composition or combination preparation of the compound, to the composition or preparation for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to process for preparation of the compound.
700/2016	LONATI S.P.A. Italy.	"Turning device for turning inside-out knitted tubular articles with pockets" D04B9/40 & D04B15/92. **143517** A turning device for knitted tubular articles, particularly for turning inside-out tubular articles with pockets that protrude from the lateral surface thereof. The turning device in question comprises a main supporting structure (2) which supports a tubular body (3) arranged with its axis (4) substantially vertical. The tubular body (3) has its upper axial end (3a) beveled along a plane that is inclined with respect to its axis (4). The turning device comprises first actuation means (5) which can be activated to perform a translation of the tubular body (3) along its axis (4) with respect to the main supporting structure (2). The tubular body (3) is insertable, with its upper axial end (3a), through an axial end of a tubular article (60) in order to turn it inside out. The turning device in question comprises second actuation means (6, 6a) which can be activated to rotate the tubular body (3) about its own axis (4), through an angle of preset breadth, with respect to the main supporting structure (2).

		 Fig. 1
40/2017	QUALCOMM INCORPORATED. U.S.A.	"NARROW BAND ACK / NACK TRANSMISSION" H04L1/16. **143518** The present disclosure provides various modifications to existing techniques for transmitting acknowledgement (ACK) and/or negative acknowledgement (NACK) in an narrow band communications system. For example, in a first aspect, an apparatus receives a downlink transmission and transmits a single tone ACK on an ACK channel using time-spreading. In another aspect, an apparatus determines whether an ACK has been received from a user equipment (UE) within a threshold amount of time, and when an ACK has not been received from the UE for at least the threshold amount of time, transmitting an indication to the UE to transmit regarding the ACK.
57/2017	QUALCOMM INCORPORATED. U.S.A.	"SMALL CELL & COMMUNICATION NETWORK RECONFIGURATION BASED ON WIRELESS DEVICE CAPABILITIES" H04W72/08 & H04W72/04. **143519**

		Aspects of the present disclosure provide a scheduling entity and method of operating the scheduling entity such that the scheduling entity reconfigures/allocates its resources based on device capabilities of the wireless devices. The scheduling entity utilizes a first resource configuration to provide communications service to one or more wireless devices associated with the scheduling entity. The scheduling entity determines a change of the one or more wireless devices, wherein the change include at least one of a capability change of a wireless device, a quality of service (QoS) requirement change of a wireless device, an addition of a wireless device, or a removal of a wireless device. Based on at least one of a predetermined time of a day or the determined change, the scheduling entity reconfigures to a second resource configuration to facilitate resource utilization of the first wireless cell. 
72/2017	VIIV HEALTHCARE UK (No.5) LIMITED. United Kingdom.	"C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS" C07J63/00, C12N9/50, A61K31/575, A61K31/56, A61K31/58 & A61P31/18. **143520** Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular,

		betulinic acid derivatives that posses unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:  Formula I These compounds are useful for the treatment of HIV and AIDS.
100/2017	FERRING B.V., Netherlands.	"Liquid Formulation of Gonadotropin" A61K47/18, A61K 9/08 & A61K9/00. **143521** The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular iquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
430/2017	Patrick John Fitzpatrick. Canada.	"A Method and Assembly for Storing and Transporting Compressed Natural Gas" F17C1/00, F17C5/06, B63B25/08 & B63B 25/24. **143522** An assembly for storing and transporting compressed fluid, such as compressed natural gas (CNG) that includes; a plurality of hexagonally stacked pipe stored in a cargo hold in or on a vessel, such as a ship or barge, that includes a lower support, side supports and a forcing mechanism that presses so strongly down on the pipes that they cannot move relative to themselves or relative to the vessel on which they are placed in any service situation. The friction between each

		of the pipes causes the plurality of pipes to act as part of the vessel in terms of its structure. Each of the pipes in the plurality of pipes is connected to a manifold system to allow for the loading and unloading of the compressed fluid. 
534/2018	NOVARTIS AG. Switzerland.	"4-METHYL-2-(1 ,1 ,1 -TRIFLUORO-2-METHYLPROPAN-2-YL)PYRIDINE COMPOUND" C07D213/26. **143523** The present invention provides a compound according to formula (1): 
883/2018	Merck Sharp & Dohme Corp. U.S.A.	"A Pharmaceutically Acceptable Salt of 4'-Substituted Nucleoside Reverse Transcriptase Inhibitor Compound" C07D487/04. **143524** The invention relates to a pharmaceutically acceptable salt of a compound of structural Formula I

		 I wherein: R is  X is O; Y is —C≡C-R^8 or -C≡N; Whereas the substituents including R1 to R^9, R^X and R^y are defined in description and claims. The present invention also provides a pharmaceutical composition comprising a 4'-substituted nucleoside compound for inhibition of HIV reverse transcriptase, for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset of AIDS.
25/2019	FAES FARMA, S.A., Spain.	"An aqueous ophthalmic pharmaceutical composition comprising bilastine as active ingredient for allergic disorders" A61K31/454, A61K47/40, A61K9/00 & A61P 27/14. **143525** The present invention relates to an aqueous ophthalmic pharmaceutical composition comprising: at least 0.4% w/v but no more than 1.0% w/v of bilastine, or a pharmaceutically acceptable salt or solvate thereof, wherein the bilastine or salt or solvate thereof is completely dissolved in the aqueous ophthalmic pharmaceutical composition; at least one β-cyclodextrin selected from the

		group consisting of unmodified β-cyclodextrin, C_1-C_6 alkyl-β-cyclodextrin, C_1-C_6 hydroxyalkyl β-cyclodextrin, C_1-C6 carboxyalkyl-β-cyclodextrin, carbonyl-β-cyclodextrin, C_2-C_6 sulfoalkylether β-cyclodextrin and mixtures thereof; and at least one pharmaceutically acceptable water-soluble gelling agent or an acceptable salt thereof, selected from the group consisting of hyaluronic acid, gellan gum and mixtures thereof; and wherein the pH value of the composition is comprised between 4 and 9, both lower and upper limits of the range included. The advantage of the invention is to provide an ophthalmic solution suitable for once-daily administration that includes high concentrations of bilastine as medicament for conditions mediated by H_1 histamine receptor, such as allergic disorders.
107/2019	BAYER CROPSCIENCE AG. Germany.	"N-BENZYL-N-CYCLOPROPYL-3-(DIHALOMETHYL)-5-HALO-1-METHYL-PYRAZOLE-4-CARBOXAMIDE COMPOUND" C07D231/16. **143526** The present invention relates to a compound of formula (IIg)  (IIg) wherein X^2 represents a chlorine or a fluorine atom, preferably a fluorine atom.
108/2019	BAYER CROPSCIENCE AG. Germany.	"N-BENZYL-N-CYCLOPROPYL-3-(DIHALOMETHYL)-5-HALO-1-METHYL-PYRAZOLE-4-CARBOXAMIDE COMPOUND" C07D231/16.

		143527 The present invention relates to a compound of formula (lIe)  (IIe) wherein X^2 represents a chlorine or a fluorine atom, preferably a fluorine atom.
109/2019	BAYER CROPSCIENCE AG. Germany.	"PROCESS FOR THE PREPARATION OF N-BENZYL-N-CYCLOPROPYL-3-(DIHALOMETHYL)-5-HALO-1-METHYL-PYRAZOLE-4-CARBOXAMIDE COMPOUND" C07D231/16. **143528** The present invention relates to a process for the preparation of compounds of formula (I), (IIb), (IIc'), (IId), (IIe), (IIf) & (IIg) according to the following scheme:  wherein • Y represents CR^5; • X^2 represents a chlorine or a fluorine atom;

		Z^1 represents a non substituted cyclopropyl or a cyclopropyl substituted by up to 2 atoms or groups which can be the same or different and which can be selected in the list consisting of halogen atoms ; cyano ; C_1-C_8-alkyl ; or C_1-C_8-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different ; Z^2 and Z^3, which can be the same or different, represent a hydrogen atom ; substituted or non substituted C_1-C_8-alkyl ; substituted or non substituted C_2-C_8-alkenyl ; substituted or non substituted C_2-C_8-alkynyl ; cyano ; isonitrile ; nitro ; a halogen atom ; substituted or non substituted C_1-C_8-alkoxy ; substituted or non substituted C_2-C_8-alkenyloxy substituted or non substituted C_2-C_8-alkynyloxy ; substituted or non substituted C_3-C_7- cycloalkyl ; substituted or non substituted C_1-C_8-alkylsulfanyl ; substituted or non substituted C1-C_8-alkylsulfonyl ; substituted or non substituted C1-C_8-alkylsulfinyl ; amino ; substituted or non substituted C_1-C_8-alkylamino ; substituted or non substituted di-C_1-C_8- alkylamino ; substituted or non substituted C_1-C_8-alkoxycarbonyl ; substituted or non substituted C_1-C_8-alkylcarbamoyl ; substituted or non substituted di-C_1-C_8-alkylcarbamoyl ; or substituted or non substituted N-C_1-C_8-alkyl-C_1-C_8-alkoxycarbamoyl ; or Z^3 and R^1 together with the consecutive carbon atoms to which they are linked form a substituted or non substituted 5-, 6- or 7-membered, partly saturated, carbo- or heterocycle comprising up to 3 heteroatoms and Z^2 is as herein described; or Z^2 and Z^3 together with the carbon atom to which they are linked form a substituted or non substituted C_3-C_7 cycloalkyl; R^1, R^2, R^3, R^4 and R^5, which can be the same or different, represent a hydrogen atom; a halogen atom ; nitro ; cyano ; isonitrile ; hydroxyl ; sulfanyl ; amino ; pentafluoro-λ^6-sulfanyl ; substituted or non substituted C_1-C_8-alkyl ; C_1-C_8-halogenoalkyl comprising up to 9 halogen atoms which can be the same or different ; substituted or

		non substituted C_1-C_8-alkylamino ; substituted or non substituted di-C_1-C_8-alkylamino ; substituted or non substituted C_1-C_8-alkoxy ; C_1-C_8-halogenoalkoxy comprising up to 9 halogen atoms which can be the same or different ; C_1-C_8-alkoxy-C_1-C_8-alkyl ; substituted or non substituted C_1-C_8-alkylsulfanyl ; C_1-C_8-halogenoalkylsulfanyl comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_2-C_8-alkenyl ; C_2-C_8-halogenoalkenyl comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_2-C_8-alkynyl ; C_2-C_8-halogenoalkynyl comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_2-C_8-alkenyloxy ; C_2-C_8-halogenoalkenyloxy comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_2-C_8-alkynyloxy ; C_2-C_8-halogenoalkynyloxy comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_3-C_7-cycloalkyl ; C_3-C_7-halogenocycloalkyl comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_3-C_7-cycloalkyl-C_1-C_8-alkyl ; substituted or non substituted C_3-C_7-cycloalkyl-C_2-C_8- alkenyl ; substituted or non substituted C_3-C7-cycloalkyl-C_2-C_8-alkynyl ; substituted or non substituted C_3-C_7-cycloalkyl-C_3-C_7-cycloalkyl ; substituted or non substituted C_1-C_8-alkylC_3-C_7-cycloalkyl ; formyl ; formyloxy ; formylamino ; carboxy ; carbamoyl ; N-hydroxycarbamoyl ; carbamate ; (hydroxyimino)-C_1-C_8-alkyl ; substituted or non substituted C_1-C_8-alkylcarbonyl ; C_1-C_8-halogenoalkylcarbonyl comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_1-C_8- alkylcarbamoyl ; substituted or non substituted di-C_1-C_8-alkylcarbamoyl ; N-(substituted or non substituted C_1-C_8-alkyloxy)carbamoyl ; substituted or non substituted C_1-C_8- alkoxycarbamoyl ; N-(substituted or non substituted C_1-C_8-alkyl)-(substituted or non substituted C_1-C_8-alkoxy)-

		carbamoyl ; substituted or non substituted C_1-C_8-alkoxycarbonyl ; C_1-C_8-halogenoalkoxycarbonyl comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_1-C_8-alkylaminocarbonyl ; di-substituted or non substituted C_1-C_8-alkylaminocarbonyl ; substituted or non substituted C_1-C_8- alkylcarbonyloxy ; C_1-C_8-halogenoalkylcarbonyloxy comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_1-C_8-alkylcarbonylamino ; C_1-C_8-halogenoalkylcarbonylamino comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_1-C_8-alkylaminocarbonyloxy ; substituted or non substituted di-C_1-C_8-alkylaminocarbonyloxy; substituted or non substituted C_1-C_8-alkyloxycarbonyloxy ; substituted or non substituted C_1-C_8-alkylsulfinyl ; C_1-C_8-halogenoalkylsulfinyl comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_1-C_8-alkylsulfonyl ; C_1-C_8- halogenoalkylsulfonyl comprising up to 9 halogen atoms which can be the same or different ; substituted or non substituted C_1-C_8-alkoxyimino ; (C_1-C_8-alkoxyimino)-C_1-C_8- alkyl ; substituted or non substituted (C_1-C_8-alkenyloxyimino)-C_1-C_8-alkyl ; (C_1-C_8-alkynyloxyimino)-C_1-C_8-alkyl ; a (benzyloxyimino)-C1-C_8-alkyl ; tri(substituted or non substituted C_1-C_8-alkyl)silyl ; tri(substituted or non substituted C_1-C_8-alkyl)silyl-C_1-C_8-alkyl ; benzyloxy which can be substituted by up to 5 groups Q; benzylsulfanyl which can be substituted by up to 5 groups Q; benzylamino which can be substituted by up to 5 groups Q; aryl which can be substituted by up to 7 groups Q; aryloxy which can be substituted by up to 7 groups Q ; arylamino which can be substituted by up to 7 groups Q ; arylsulfanyl which can be substituted by up to 7 groups Q ; aryl-C_1-C_8alkyl which can be substituted by up to 7 groups Q ; aryl-C_2-C_8-alkenyl which can be substituted by up to 7 groups Q; aryl-C_2-C_8-alkynyl which can be substituted by up to 7 groups Q; pyridinyl which

		can be substituted by up to 4 groups Q; pyridinyloxy which can be substituted by up to 4 groups Q; aryl-C_3-C_7-cycloalkyl which can be substituted by up to 7 groups Q; or Two vicinal substituents R together with the consecutive carbon atoms to which they are linked form a substituted or non substituted 5- or 6-membered, saturated, carbo- or hetero-cycle comprising up to 3 heteroatoms and the other substituents R are as herein- described; or • R^1 and Z^3 together with the consecutive carbon atoms to which they are linked form a substituted or non substituted 5-, 6- or 7-membered, partly saturated, carbo- or heterocycle comprising up to 3 heteroatoms, and R^2 to R^5 are as herein-described.
110/2019	BAYER CROPSCIENCE AG. Germany.	"N-BENZYL-N-CYCLOPROPYL-3-(DIHALOMETHYL)-5-HALO-1-METHYL-PYRAZOLE-4-CARBOXAMIDE COMPOUND" C07D231/16. **143529** The present invention relates to a compound of formula (lIf)  (IIf) wherein X^2 represents a chlorine or a fluorine atom, preferably a fluorine atom.
111/2019	BAYER CROPSCIENCE AG. Germany.	"N-BENZYL-N-CYCLOPROPYL-3-(DIHALOMETHYL)-5-HALO-1-METHYL-PYRAZOLE-4-CARBOXAMIDE COMPOUND" C07D231/16. **143530**

		The present invention relates to a compound of formula (lIb)  (IIb) wherein X^2 represents a chlorine or a fluorine atom, preferably a fluorine atom.
112/2019	BAYER CROPSCIENCE AG. Germany.	"N-BENZYL-N-CYCLOPROPYL-3-(DIHALOMETHYL)-5-HALO-1-METHYL-PYRAZOLE-4-CARBOXAMIDE COMPOUND" C07D231/16 & C07D231/16. **143531** The present invention relates to a compound of formula (lIc')  (IIc') wherein X^2 represents a chlorine or a fluorine atom, preferably a fluorine atom; and W^3 represent a halogen atom, preferably a chlorine atom.
113/2019	BAYER CROPSCIENCE AG. Germany.	"N-BENZYL-N-CYCLOPROPYL-3-(DIHALOMETHYL)-5-HALO-1-METHYL-PYRAZOLE-4-CARBOXAMIDE COMPOUND" C07D231/16. **143532** The present invention relates to a compound of formula (lId)

		 (IId) wherein X^2 represents a chlorine or a fluorine atom, preferably a fluorine atom.
194/2019	VIIV HEALTHCARE UK (No.5) LIMITED. United Kingdom.	"A pharmaceutically acceptable salt of C-3 and C-17 Modified triterpenoids as HIV-I Inhibitor" C07J63/00, C12N9/50, A61K31/575, A61K31/56, A 61K 31/58 & A61P 31/18. **143533** The present invention provides a pharmaceutically acceptable salt of a compound wherein said salt is the salt of formula 1:  The pharmaceutically acceptable salt of a compound having drug and bio-affecting properties, its pharmaceutical composition thereof. In particular, salt of betulinic acid possess unique antiviral activity are provided as HIV maturation inhibitors and are useful for the treatment of HIV and AIDS.
287/2019	CASALE SA. Switzerland.	"A PROCESS FOR NITRIC ACID PRODUCTION" C01B21/26, C01B21/28 & C01C1/04. **143534**

		Integrated process for the synthesis of ammonia and nitric acid including: a) production of an ammonia make-up synthesis gas, comprising steam reforming of a hydrocarbon feedstock under provision of steam reforming heat; catalytic conversion of said make-up synthesis gas into ammonia; catalytic oxidation of a stream of ammonia obtaining a process gas; absorption of said process gas with water obtaining nitric acid, wherein at least a portion of the steam reforming heat is recovered from said hot process gas.

NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Applicant
15/06/2020			
1.	20418	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
2.	20419	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
3.	20420	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
4.	20421	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
5.	20422	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
6.	20423	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
7.	20424	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
8.	20425	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
9.	20426	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
10.	20427	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
11.	20428	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
12.	20429	Textile Articles, Dresses & Clothes (Class-13)	Maria B Designs Private Limited
16/06/2020			
13.	20430	beverage cup with removable lid (Class-03))	Batsam Group S.a.r.l.
18/06/2020			
14.	20431	AUTOMOBILE (CLASS-01)	TOYOTA JIDOSHA KABUSHIKI KAISHA
15.	20432	AUTOMOBILE (CLASS-01)	TOYOTA JIDOSHA KABUSHIKI KAISHA

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Applicant
		15/06/2020	
1.	20039	Tyre (Class-03)	Jianxin Tyre (Fujian) Co., Ltd
2.	20092	Football (Class-06)	Madrigal Sports (Pvt) Ltd
3.	20041	Dispenser (Class-12)	Unilever PLC
4.	20087	Brain Imaging Tool for Medical Diagonosis (Class-03)	Muhammad Hamza Asif Nizami, Umer Asgher, Sara Ali, Yasar Ayaz and Muhammad Jawad Khan
5.	19998	Mobile Phone (Class-03)	M/s. FOXXCOM (Pvt.) LIMITED
6.	19997	Pet Bottle (Class-03)	M/s. Shangrila (Private) Limited
7.	19996	Mobile Phone (Class-03)	M/s. FOXXCOM (Pvt.) LIMITED
8.	19461	Instrument Panel for an Automobile (Class-01)	Toyota Jidosha Kabushiki Kaisha
9.	19841	Brooch (Jewelry)(Class-01)	MACON & LESQUOY
10.	20097	Automobile (Class-01)	Toyota Jidosha Kabushiki Kaisha
11.	20055	Radiator grill for an automobile (Class-01)	Hino Motors, Ltd
12.	20040	Compressor Unit (Class-03)	Maschinenfabrik Rieter AG
13.	20044	Moccasin (Footwear)	Dil Bahar Plastic Industry
14.	20103	Smart Payment Notification Device (Class-12)	Alibaba Group Holding Limited
15.	20091	Football (Class-06)	Madrigal Sports (Pvt) Ltd
16.	20000	Battery for Electric Power Unit (Class-03)	Honda Motor Co., Ltd
17.	20003	Battery Module for Electric Power Unit (Class-03)	Honda Motor Co., Ltd
18.	19634	Machine (Class-01)	CDE Asia Limited
19.	19999	Electric Power Unit (Class-03)	Honda Motor Co., Ltd
20.	19927	A Motorcycle (Class-01)	Honda Motor Co., Ltd
21.	20001	Electric Power Unit (Class-03)	Honda Motor Co., Ltd

-sd-
(Dr. Muhammad Fayyaz Ahmad)
Controller of Patents
& Registrar of Designs
Ph: 99230591